Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | REPL |
---|---|---|
09:32 ET | 10990 | 10.135 |
09:34 ET | 100 | 10.1 |
09:36 ET | 100 | 10.055 |
09:38 ET | 100 | 10 |
09:39 ET | 1049 | 9.98 |
09:41 ET | 1321 | 9.93 |
09:43 ET | 2844 | 9.975 |
09:45 ET | 850 | 10.02 |
09:48 ET | 4636 | 10.05 |
09:50 ET | 5778 | 10.03 |
09:52 ET | 500 | 10.03 |
09:54 ET | 1300 | 10.02 |
09:56 ET | 700 | 10.035 |
09:57 ET | 100 | 10.01 |
09:59 ET | 4400 | 10.01 |
10:01 ET | 5601 | 9.98 |
10:03 ET | 300 | 9.975 |
10:06 ET | 700 | 9.985 |
10:08 ET | 700 | 9.97 |
10:10 ET | 5002 | 10.02 |
10:12 ET | 31864 | 10.075 |
10:14 ET | 1310 | 10.1 |
10:15 ET | 1000 | 10.1 |
10:17 ET | 8288 | 10.14 |
10:19 ET | 2871 | 10.2 |
10:21 ET | 3631 | 10.145 |
10:26 ET | 700 | 10.16 |
10:28 ET | 2789 | 10.16 |
10:30 ET | 342 | 10.16 |
10:32 ET | 610 | 10.14 |
10:33 ET | 750 | 10.13 |
10:35 ET | 3984 | 10.2 |
10:37 ET | 100 | 10.195 |
10:39 ET | 200 | 10.17 |
10:44 ET | 600 | 10.17 |
10:46 ET | 200 | 10.18 |
10:48 ET | 1501 | 10.16 |
10:51 ET | 301 | 10.15 |
10:53 ET | 2012 | 10.1 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Replimune Group Inc | 690.7M | -3.1x | --- |
ProKidney Corp | 695.2M | -4.1x | --- |
Olema Pharmaceuticals Inc | 699.2M | -5.8x | --- |
Nuvation Bio Inc | 680.4M | -1.3x | --- |
Savara Inc | 716.0M | -9.9x | --- |
Alumis Inc | 663.6M | -3.9x | --- |
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $690.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 68.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-3.27 |
Book Value | $6.10 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.